• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

核转运因子 2 作为头颈部鳞状细胞癌的新型生物标志物,与 T/B 细胞受体信号通路相关。

Nuclear Transporting Factor 2 as a Novel Biomarker of Head and Neck Squamous Cell Carcinoma and Associated with T/B Cell Receptor Signaling Pathway.

机构信息

The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei-MOST) & Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, 430079 Wuhan, China.

出版信息

Biomed Res Int. 2022 Feb 4;2022:2885323. doi: 10.1155/2022/2885323. eCollection 2022.

DOI:10.1155/2022/2885323
PMID:35155672
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8837431/
Abstract

OBJECTIVE

This study is aimed at exploring the role of nuclear transporting factor 2 (NUTF2) in head and neck squamous cell carcinoma (HNSCC) based on The Cancer Genome Atlas (TCGA) database.

METHODS

We obtained 528 HNSCC patients' clinical data from TCGA and performed expression level analysis of NUTF2. Gene Sets Enrichment Analysis (GSEA) was conducted to identify NUTF2-associated regulatory mechanisms in HNSCC. In addition, several other tools were used to enrich the regulatory network.

RESULTS

We found that NUTF2 was significantly upregulated ( < 0.001) in HNSCC. We then observed that higher NUTF2 is associated with poorer overall survival and disease-free survival. Further, by using Cox analyses, we determined high NUTF2 as an independent risk factor of predicting poorer overall survival. Tumor immune infiltration analysis revealed a significantly negative correlation between NUTF2 expression and the level of tumor infiltrated CD8 T cell and B cell, suggesting that NUTF2 may be involved in the immune regulation of HNSCC. Gene sets related to T/B cell receptor signaling pathways were differentially enriched based on the NUTF2 expression phenotype. KEGG pathways were used to show that NUTF2 may affect proliferation, differentiation, and immune response of T/B cell through regulating PI3K/AKT, NFB, MAPK, and Calcium signaling pathways.

CONCLUSION

NUTF2 might be a valuable biomarker for HNSCC and correlated with T/B cell receptor signaling pathway.

摘要

目的

本研究旨在基于癌症基因组图谱(TCGA)数据库探讨核转运因子 2(NUTF2)在头颈部鳞状细胞癌(HNSCC)中的作用。

方法

我们从 TCGA 获得了 528 例 HNSCC 患者的临床数据,并对 NUTF2 的表达水平进行了分析。采用基因集富集分析(GSEA)鉴定 NUTF2 与 HNSCC 相关的调控机制。此外,还使用了其他几种工具来丰富调控网络。

结果

我们发现 NUTF2 在 HNSCC 中显著上调(<0.001)。我们观察到 NUTF2 表达水平越高,总生存率和无病生存率越低。进一步通过 Cox 分析,我们确定高 NUTF2 是预测总生存率较差的独立危险因素。肿瘤免疫浸润分析显示 NUTF2 表达与肿瘤浸润 CD8 T 细胞和 B 细胞水平呈显著负相关,表明 NUTF2 可能参与 HNSCC 的免疫调节。基于 NUTF2 表达表型,差异富集了与 T/B 细胞受体信号通路相关的基因集。KEGG 通路显示,NUTF2 可能通过调节 PI3K/AKT、NF-κB、MAPK 和钙信号通路影响 T/B 细胞的增殖、分化和免疫反应。

结论

NUTF2 可能是 HNSCC 的一个有价值的生物标志物,与 T/B 细胞受体信号通路相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c7e/8837431/0d269a4f898d/BMRI2022-2885323.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c7e/8837431/ae811b72cc4e/BMRI2022-2885323.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c7e/8837431/7c5408dd1c48/BMRI2022-2885323.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c7e/8837431/fe45972d0e86/BMRI2022-2885323.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c7e/8837431/98bfd6526960/BMRI2022-2885323.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c7e/8837431/acdfc194838c/BMRI2022-2885323.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c7e/8837431/901c22d45b8e/BMRI2022-2885323.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c7e/8837431/0d269a4f898d/BMRI2022-2885323.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c7e/8837431/ae811b72cc4e/BMRI2022-2885323.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c7e/8837431/7c5408dd1c48/BMRI2022-2885323.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c7e/8837431/fe45972d0e86/BMRI2022-2885323.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c7e/8837431/98bfd6526960/BMRI2022-2885323.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c7e/8837431/acdfc194838c/BMRI2022-2885323.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c7e/8837431/901c22d45b8e/BMRI2022-2885323.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1c7e/8837431/0d269a4f898d/BMRI2022-2885323.007.jpg

相似文献

1
Nuclear Transporting Factor 2 as a Novel Biomarker of Head and Neck Squamous Cell Carcinoma and Associated with T/B Cell Receptor Signaling Pathway.核转运因子 2 作为头颈部鳞状细胞癌的新型生物标志物,与 T/B 细胞受体信号通路相关。
Biomed Res Int. 2022 Feb 4;2022:2885323. doi: 10.1155/2022/2885323. eCollection 2022.
2
Identification of NUTF2 as a Candidate Diagnostic and Prognostic Biomarker Associated with Immune Infiltration in Head and Neck Squamous Cell Carcinoma.鉴定NUTF2作为与头颈部鳞状细胞癌免疫浸润相关的候选诊断和预后生物标志物。
Onco Targets Ther. 2021 Dec 22;14:5455-5467. doi: 10.2147/OTT.S337469. eCollection 2021.
3
NUTF2 as a Prognostic Indicator and Potential Therapeutic Target in Head and Neck Squamous Cell Carcinoma.NUTF2 作为头颈部鳞状细胞癌的预后指标和潜在治疗靶点。
Genet Test Mol Biomarkers. 2022 Dec;26(12):553-563. doi: 10.1089/gtmb.2022.0102.
4
SLA2 is a prognostic marker in HNSCC and correlates with immune cell infiltration in the tumor microenvironment.SLA2 是 HNSCC 的预后标志物,与肿瘤微环境中的免疫细胞浸润相关。
Eur Arch Otorhinolaryngol. 2024 Jan;281(1):427-440. doi: 10.1007/s00405-023-08213-4. Epub 2023 Sep 9.
5
Identification of CCT3 as a prognostic factor and correlates with cell survival and invasion of head and neck squamous cell carcinoma.鉴定 CCT3 为一个预后因素,并与头颈部鳞状细胞癌的细胞存活和侵袭相关。
Biosci Rep. 2021 Oct 29;41(10). doi: 10.1042/BSR20211137.
6
A model of seven immune checkpoint-related genes predicting overall survival for head and neck squamous cell carcinoma.一种基于七个免疫检查点相关基因的模型,可预测头颈部鳞状细胞癌的总生存期。
Eur Arch Otorhinolaryngol. 2021 Sep;278(9):3467-3477. doi: 10.1007/s00405-020-06540-4. Epub 2021 Jan 15.
7
Development and validation of a fourteen- innate immunity-related gene pairs signature for predicting prognosis head and neck squamous cell carcinoma.开发和验证十四对固有免疫相关基因对预测头颈部鳞状细胞癌预后的标志。
BMC Cancer. 2020 Oct 20;20(1):1015. doi: 10.1186/s12885-020-07489-7.
8
Tumor Mutation Burden, Immune Cell Infiltration, and Construction of Immune-Related Genes Prognostic Model in Head and Neck Cancer.头颈部癌中的肿瘤突变负担、免疫细胞浸润和免疫相关基因预后模型的构建。
Int J Med Sci. 2021 Jan 1;18(1):226-238. doi: 10.7150/ijms.51064. eCollection 2021.
9
Transcriptome analysis reveals the link between lncRNA-mRNA co-expression network and tumor immune microenvironment and overall survival in head and neck squamous cell carcinoma.转录组分析揭示长非编码 RNA-mRNA 共表达网络与头颈部鳞状细胞癌肿瘤免疫微环境和总生存期的关系。
BMC Med Genomics. 2020 Mar 30;13(1):57. doi: 10.1186/s12920-020-0707-0.
10
Expression and Possible Molecular Mechanisms of microRNA-205-5p in Patients With Head and Neck Squamous Cell Carcinoma.头颈部鳞状细胞癌患者中 microRNA-205-5p 的表达及可能的分子机制。
Technol Cancer Res Treat. 2020 Jan-Dec;19:1533033820980110. doi: 10.1177/1533033820980110.

引用本文的文献

1
A novel neutrophil extracellular trap signature to predict prognosis and immunotherapy response in head and neck squamous cell carcinoma.一种新的中性粒细胞胞外诱捕网标志物,可预测头颈部鳞状细胞癌的预后和免疫治疗反应。
Front Immunol. 2022 Sep 23;13:1019967. doi: 10.3389/fimmu.2022.1019967. eCollection 2022.

本文引用的文献

1
Nuclear Transport Factor 2 (NTF2) suppresses WM983B metastatic melanoma by modifying cell migration, metastasis, and gene expression.核转运因子 2(NTF2)通过改变细胞迁移、转移和基因表达来抑制 WM983B 转移性黑色素瘤。
Sci Rep. 2021 Dec 8;11(1):23586. doi: 10.1038/s41598-021-02803-0.
2
Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.脑垂体中叶机能减退症和 Prascend(培高利特片剂)对马的内分泌和免疫功能的影响。
Domest Anim Endocrinol. 2021 Jan;74:106531. doi: 10.1016/j.domaniend.2020.106531. Epub 2020 Jul 29.
3
Long Noncoding RNA LINC00173 Promotes NUTF2 Expression Through Sponging miR-765 and Facilitates Tumorigenesis in Glioma.
长链非编码RNA LINC00173通过吸附miR-765促进NUTF2表达并促进胶质瘤的肿瘤发生。
Cancer Manag Res. 2020 Aug 12;12:7211-7217. doi: 10.2147/CMAR.S262279. eCollection 2020.
4
Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy.头颈部鳞状细胞癌患者免疫细胞的免疫检查点表达及化疗和免疫治疗的调节。
Int J Mol Sci. 2020 Jul 22;21(15):5181. doi: 10.3390/ijms21155181.
5
TIMER2.0 for analysis of tumor-infiltrating immune cells.TIMER2.0 用于分析肿瘤浸润免疫细胞。
Nucleic Acids Res. 2020 Jul 2;48(W1):W509-W514. doi: 10.1093/nar/gkaa407.
6
The putative endogenous AHR ligand ITE reduces JAG1 and associated NOTCH1 signaling in triple negative breast cancer cells.假定的内源性 AHR 配体 ITE 可减少三阴性乳腺癌细胞中的 JAG1 和相关的 NOTCH1 信号。
Biochem Pharmacol. 2020 Apr;174:113845. doi: 10.1016/j.bcp.2020.113845. Epub 2020 Feb 4.
7
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
8
Immune checkpoint inhibitors for head and neck squamous cell carcinoma: Current landscape and future directions.头颈部鳞状细胞癌的免疫检查点抑制剂:现状与未来方向。
Head Neck. 2019 Oct;41 Suppl 1:4-18. doi: 10.1002/hed.25930.
9
The changing therapeutic landscape of head and neck cancer.头颈部癌症治疗领域的变化。
Nat Rev Clin Oncol. 2019 Nov;16(11):669-683. doi: 10.1038/s41571-019-0227-z. Epub 2019 Jun 12.
10
Heterogeneity of the Head and Neck Squamous Cell Carcinoma Immune Landscape and Its Impact on Immunotherapy.头颈部鳞状细胞癌免疫景观的异质性及其对免疫治疗的影响。
Front Cell Dev Biol. 2019 Apr 9;7:52. doi: 10.3389/fcell.2019.00052. eCollection 2019.